Blog Elements - Turf Matters

Half Sized Blog Element (Single Author Style)

Half Sized Blog Element (Multi Author Style)

ISEKI UK proud to be part of Watcombe’s journey

February 17, 2025/in News, Press Release/by Admin

ISEKI UK proud to be part of Watcombe’s journey: Seventeen months ago, a new under-14 girls’ football team was started in South Devon for girls’ who were unhappy at their current clubs. Fast forward a season and a half, and Watcombe Wanderers have won promotion in their first season and now have two teams whose […]

Why Are Biological Companies Struggling for Investment

February 17, 2025/in News, Press Release/by Admin

Why Are Biological Companies Struggling for Investment: In recent years, the agricultural biologicals sector has witnessed significant growth. The global market was estimated at $16.7 billion in 2024 and is projected to reach $31.8 billion by 2029. This surge underscores the increasing demand for sustainable agricultural solutions. However, early-stage startups, particularly those in pre-seed and […]

ISEKI UK proud to be part of Watcombe’s journey

February 17, 2025/in News, Press Release/by Admin

Why Are Biological Companies Struggling for Investment

February 17, 2025/in News, Press Release/by Admin

Full Sized Blog Element (Big Preview Pic)

ISEKI UK proud to be part of Watcombe’s journey

February 17, 2025/in News, Press Release/by Admin

ISEKI UK proud to be part of Watcombe’s journey: Seventeen months ago, a new under-14 girls’ football team was started in South Devon for girls’ who were unhappy at their current clubs.

Fast forward a season and a half, and Watcombe Wanderers have won promotion in their first season and now have two teams whose kits are proudly sponsored by ISEKI UK and Ireland.

ISEKI UK proud to be part of Watcombe’s journey

In September 2023, team manager Martin Campbell, a fully licenced coach, was approached to start the team, and during the recruitment process, he received a message from ISEKI Vehicle Sales Manager Phil Catley about his daughter, Maddie.

After starting the season late due to not having enough players, Maddie and the other girls quickly formed a formidable team, eventually finishing second on the last day of the season to claim promotion to Division Two.

With the football side of the team performing beyond expectations, Martin wanted to build the team’s identity with new kits and hoodies before they started their second season. To do this, he sent a message to the parents, and Phil replied.

“They were playing like footballers, so we wanted them to look like footballers,” Martin said. “It can seem like a small thing, but before I joined the ambulance service I was in the service industry for 25 years in sales. Every time you put on a new suit, you feel like someone; you feel like something, and that’s what I wanted for the girls with their own kit.

“Like any grassroots club, we rely on volunteers and parents to drive the club, and when it came to kit sponsorship, we asked the parents, and Phil came forward and said I might be able to help.

“Like anything, people come forward with good intentions, but we all sat here thinking, ‘Why is a big national company going to be interested in a little backstreet girls’ football team on the outskirts of Newton Abbott.’

“But the response from ISEKI was positive, and they sponsored two kits and hoodies for the girls, and I have to say they look outstanding.

Without the sponsorship from ISEKI, the girls wouldn’t be able to play football with a nice kit on their backs and be proud of them. They wear the hoodies when they go to school or when they’re walking down the street with their mum and dad. So, what might seem like a small thing has made a significant difference to our team.

We are currently placed second in the second division and are chasing promotion to the first division, which will be a massive achievement for a new team to go from third division to first division in two years.”

“Women’s football is enjoying massive growth these days, so to be able to support an up-and-coming grassroots team is something to be very proud of especially with the amount of work we do with the GMA’s Pitch Advisory Service in advising on the supply of machinery to local sports clubs” said Alan Prickett Sales Director of ISEKI Uk & Ireland.

For the latest industry news visit turfmatters.co.uk/news

Get all of the big headlines, pictures, opinions and videos on stories that matter to you.

Follow us on Twitter and Instagram for fun, fresh and engaging content.

You can also find us on Facebook for more of your must-see news, features, videos and pictures from Turf Matters.

Why Are Biological Companies Struggling for Investment

February 17, 2025/in News, Press Release/by Admin

Why Are Biological Companies Struggling for Investment: In recent years, the agricultural biologicals sector has witnessed significant growth. The global market was estimated at $16.7 billion in 2024 and is projected to reach $31.8 billion by 2029. This surge underscores the increasing demand for sustainable agricultural solutions.

However, early-stage startups, particularly those in pre-seed and seed stages, face substantial challenges in securing investment. While more established companies like Switch Bioworks, Elicit Plant, Solasta, Agospheres, Biotalys, Micropep, Catalera, Botanical Solution, and BioConsortia successfully obtained funding in 2024, emerging enterprises often struggle to attract similar attention. This disparity is partly due to investors’ heightened expectations and a preference for ventures with proven technologies or those nearing revenue generation.

Why Are Biological Companies Struggling for Investment

Current Investment Trends in Agricultural Biologicals

Geographically, Europe-focused venture capitalists (VCs) are leading the way in funding biological companies. Looking ahead to 2025, there is cautious optimism that U.S. investors will increase their participation, particularly as interest rates decline. However, uncertainties related to tariffs, the farm economy, and government agency (EPA) budgets persist, which could impact investment decisions.

The investment landscape has changed significantly. The willingness to fund biological companies at the high levels seen 3-5 years ago has diminished. Investors today possess more profound industry knowledge, making them more selective. They are increasingly drawn to companies with well-defined business models, clear paths to market impact, and solid financial planning.

The Challenges of Building a Successful Biologicals Business

Succeeding in the biological sector demands patience, effort, and strategic focus. Investors often have unrealistic expectations regarding market development, leading to an oversaturated and unsustainable market. Moving forward, I hope to see more realism in investor sentiment, which will benefit the entire industry by fostering sustainable growth and innovation.

Additionally, recent failures in agri-biological investments have made investors more cautious. To attract funding, companies must demonstrate:

Quality-driven research & development
Efficient spending and cost management
Clear and executable go-to-market strategies

Companies that meet these expectations will have a higher chance of securing funding, thereby improving the overall quality of investments in the sector.

Regulatory Barriers and Their Impact on Investment

My experience raising investment for Bionema has reinforced one of the most critical issues in this sector: the lengthy and costly regulatory approval process for biopesticides. While venture capital investors are interested in biological solutions, many are deterred by the extended timelines required to bring products to market. Unlike conventional agrochemicals, biopesticides require approximately £5-8 million per product for global registration, which is manageable for companies like Bionema. Still, the real challenge is the time needed for regulatory approval. This process often delays market entry by 5-7 years in the EU, 2-3 years in NA and 12 months in Brazil after biopesticides regulatory reform, making it difficult for investors to commit to early-stage funding.

Instead of investing in Series A or Series B rounds, I have observed greater interest from agrochemical multinationals in acquiring or licensing biological technologies. While this demonstrates the commercial viability of biologicals, it also signals a reluctance among large corporations to invest in the sector’s long-term growth. If the biological industry is to thrive and compete with synthetic chemicals, substantial investment will be required to accelerate development and commercialisation.

Moreover, biopesticide regulations must be harmonised globally to streamline approvals and reduce market entry barriers. The fragmented regulatory environment forces companies to undergo separate and costly registration processes in different regions, further discouraging investment. Unless regulatory agencies align their frameworks, the biological sector will struggle with slow growth and limited funding.

Key Areas of Growth in Agricultural Biologicals

From an industry perspective, biologicals are thriving, particularly in nitrogen use efficiency, nitrogen fixation, and biocontrol. New application methods like planter box technologies are experiencing significant growth and scaling.

For farmers, return on investment (ROI) remains the key driver. In the current economic climate, growers are seeking efficiency-enhancing solutions, including:
✔ Fertilizer replacements
✔ Yield enhancers
✔ Abiotic stress mitigation products

As growers become more educated about biologicals, their adoption rates are increasing rapidly, leading to further investment in these technologies.

Investor Expectations for the Future

Historically, venture capital has played a key role in funding biologicals and will continue to do so. However, some investors have overly enthusiastic expectations regarding short-term returns. As VCs gain a deeper understanding of the sector, we expect them to invest more targeted and strategically.

Private equity firms are taking a more cautious, sustainable approach to investment. These firms focus on long-term flexibility and adaptability, recognising the rapidly evolving nature of the AgBio industry.

The Reality of Raising Capital in 2025

The current investment climate in biorationals mirrors the broader agricultural market’s bearish trend. However, market growth in this sector, driven by:
✔ Public and grower demand for sustainable agriculture
✔ Stricter regulatory policies limiting chemical options

Farmers are expected to increase their adoption of biologicals, but only for science-backed solutions with proven efficacy that deliver real value.

Finding new capital to fund early-stage biological companies will remain challenging in 2025. Investors are becoming more critical and selective, favouring companies that:
✔ Have a proven technology platform
✔ Are generating (or near generating) revenue
✔ Have a clear pathway to profitability

As a result, securing seed funding or Series A investment will be challenging over the next 1-2 years.

The Long-Term Future of BioAg Investment

Despite the current challenges, biologicals attract significant interest, mainly from companies traditionally focused on agrochemicals and fertilisers. These corporations recognise the growing regulatory and consumer-driven shift toward sustainable agricultural solutions. However, we have seen a slight decline in mergers and acquisitions (M&A) activity and the closure of some companies in this sector. This highlights the difficulty of sustaining a BioAg business—balancing high investment costs with the need for consistent financial returns. Despite this, the long-term strategic value of biologicals is undeniable. The agricultural industry is undergoing a significant shift, and biologicals will be crucial in this transformation. Investors may remain cautious, but their interest in scalable, science-backed solutions will persist.

Final Thoughts

While securing investment remains a significant challenge for early-stage biological companies, those focusing on innovation, strategic planning, and strong financial models will continue attracting funding. Realism in investor expectations is key to building a sustainable and impactful BioAg industry.

The future of biologicals is bright, but companies must prove their value with solid science, strong business cases, and a clear go-to-market strategy.

For the latest industry news visit turfmatters.co.uk/news

Get all of the big headlines, pictures, opinions and videos on stories that matter to you.

Follow us on Twitter and Instagram for fun, fresh and engaging content.

You can also find us on Facebook for more of your must-see news, features, videos and pictures from Turf Matters.

Half Sized Blog Element (Single Author Style)

Half Sized Blog Element (Multi Author Style)

ISEKI UK proud to be part of Watcombe’s journey

Why Are Biological Companies Struggling for Investment

ISEKI UK proud to be part of Watcombe’s journey

Why Are Biological Companies Struggling for Investment

Full Sized Blog Element (Big Preview Pic)

ISEKI UK proud to be part of Watcombe’s journey

ISEKI UK proud to be part of Watcombe’s journey: Seventeen months ago, a new under-14 girls’ football team was started in South Devon for girls’ who were unhappy at their current clubs.

Why Are Biological Companies Struggling for Investment

Current Investment Trends in Agricultural Biologicals

The Challenges of Building a Successful Biologicals Business

Regulatory Barriers and Their Impact on Investment

Key Areas of Growth in Agricultural Biologicals

Investor Expectations for the Future

The Reality of Raising Capital in 2025

The Long-Term Future of BioAg Investment

Final Thoughts

RESOURCES

CONTACT

CONNECT